JO
KYTX icon

John Overdeck’s Kyverna Therapeutics KYTX Stock Holding History

John Overdeck’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$457K Sell
51,319
-130,296
-72% -$1.16M ﹤0.01% 4216
2026
Q1 		$1.57M Sell
181,615
-23,652
-12% -$197K ﹤0.01% 2946
2025
Q4 		$1.93M Buy
205,267
+72,816
+55% +$541K ﹤0.01% 2465
2025
Q3 		$795K Buy
132,451
+11,867
+10% +$47.4K ﹤0.01% 2730
2025
Q2 		$370K Sell
120,584
-2,393
-2% -$5.92K ﹤0.01% 2709
2025
Q1 		$237K Sell
122,977
-58,677
-32% -$173K ﹤0.01% 2802
2024
Q4 		$679K Buy
181,654
+58,800
+48% +$282K ﹤0.01% 2385
2024
Q3 		$601K Sell
122,854
-33,442
-21% -$258K ﹤0.01% 2378
2024
Q2 		$1.17M Buy
156,296
+135,454
+650% +$2.07M ﹤0.01% 1902
2024
Q1 		$518K Buy
+20,842
New +$582K ﹤0.01% 2314

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

John Overdeck's KYTX Position: Q2 2026 in Review

John Overdeck reduced its Kyverna Therapeutics (KYTX) stake by 72% in Q2 2026, selling an estimated $1.16M and leaving 51,319 shares worth $457K. The position accounts for ﹤0.01% of the portfolio, ranked #4216.

John Overdeck first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.93M in Q4 2025. 119 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • John Overdeck held 51,319 shares of Kyverna Therapeutics worth $457K as of Q2 2026.
  • John Overdeck sold 130,296 Kyverna Therapeutics shares in Q2 2026, an estimated $1.16M.
  • Kyverna Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4216 holding.
  • John Overdeck first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • John Overdeck's Kyverna Therapeutics position peaked at $1.93M in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.